Prolastin



Indications and Reactions:

Role Indications Reactions
Primary
Alpha-1 Anti-trypsin Deficiency 92.4%
Drug Use For Unknown Indication 1.7%
Alpha-1 Anti-trypsin 1.2%
Emphysema 1.2%
Accidental Exposure 0.6%
Idiopathic Thrombocytopenic Purpura 0.6%
Panniculitis 0.6%
Product Used For Unknown Indication 0.6%
Pruritus 0.6%
Rash 0.6%
Urticaria 17.1%
Pyrexia 10.5%
Infusion Related Reaction 6.6%
White Blood Cell Count Decreased 6.6%
Fatigue 5.3%
Rash 5.3%
Anaphylactic Reaction 3.9%
Drug Hypersensitivity 3.9%
Dyspnoea 3.9%
Influenza Like Illness 3.9%
Tachycardia 3.9%
Tachypnoea 3.9%
Throat Tightness 3.9%
Tremor 3.9%
Weight Increased 3.9%
Alpha-1 Anti-trypsin Deficiency 2.6%
Chest Discomfort 2.6%
Headache 2.6%
Migraine 2.6%
Nausea 2.6%
Secondary
Alpha-1 Anti-trypsin Deficiency 80.0%
Product Used For Unknown Indication 10.0%
Emphysema 5.0%
Rheumatoid Arthritis 5.0%
Dyspnoea Exertional 7.1%
Infusion Site Extravasation 7.1%
Lung Infection 7.1%
Nausea 7.1%
Postmenopausal Haemorrhage 7.1%
Rash Macular 7.1%
Rash Maculo-papular 7.1%
Respiratory Tract Infection 7.1%
Sinus Arrest 7.1%
Tachypnoea 7.1%
Unevaluable Event 7.1%
Upper Respiratory Tract Infection 7.1%
Venous Thrombosis Limb 7.1%
Weight Increased 7.1%
Concomitant
Alpha-1 Anti-trypsin Deficiency 54.3%
Osteoporosis 6.5%
Asthma 4.3%
Chronic Obstructive Pulmonary Disease 4.3%
Coccidioidomycosis 4.3%
Smoking Cessation Therapy 4.3%
Benign Prostatic Hyperplasia 2.2%
Blood Cholesterol Abnormal 2.2%
Bronchiectasis 2.2%
Gastritis 2.2%
Hypothyroidism 2.2%
Lower Respiratory Tract Inflammation 2.2%
Nicotine Dependence 2.2%
Pain 2.2%
Panniculitis 2.2%
Pulmonary Arterial Hypertension 2.2%
Dyspnoea 11.1%
Infusion Related Reaction 7.4%
Pyrexia 7.4%
Retching 7.4%
Viral Infection 7.4%
Weight Increased 7.4%
Anxiety 3.7%
Contusion 3.7%
Diarrhoea 3.7%
Dizziness 3.7%
Dyspnoea Exertional 3.7%
Hypoaesthesia 3.7%
Incorrect Drug Administration Rate 3.7%
Influenza Like Illness 3.7%
Infusion Site Pain 3.7%
Intentional Drug Misuse 3.7%
Muscle Spasms 3.7%
Myalgia 3.7%
Oesophageal Pain 3.7%
Rash 3.7%